HITGEN INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.28 CNY | +0.49% |
|
-6.12% | -18.08% |
| Apr. 24 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 23 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 436M 60.19M | Sales 2025 * | 505M 69.65M | Capitalization | 4.91B 677M |
|---|---|---|---|---|---|
| Net income 2024 * | 50M 6.9M | Net income 2025 * | 61M 8.42M | EV / Sales 2024 * | 11.3 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.72 x |
| P/E ratio 2024 * |
96.9
x | P/E ratio 2025 * |
80.1
x | Employees | 452 |
| Yield 2024 * |
0.08% | Yield 2025 * |
0.08% | Free-Float | 33.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.49% | ||
| 1 week | -6.12% | ||
| Current month | -9.17% | ||
| 1 month | -5.39% | ||
| 3 months | -2.85% | ||
| 6 months | -24.71% | ||
| Current year | -18.08% |
1 week
11.95
12.78
1 month
11.9514.49
Current year
8.8517.62
1 year
8.8519.35
3 years
8.8533.19
5 years
8.8561.99
10 years
8.8561.99
| Managers | Title | Age | Since |
|---|---|---|---|
Jin Li
CEO | Chief Executive Officer | 61 | 12-02-21 |
Eliza Liu
DFI | Director of Finance/CFO | 54 | 23-04-26 |
Barry A Morgan
CTO | Chief Tech/Sci/R&D Officer | 77 | 16-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin Li
CEO | Chief Executive Officer | 61 | 12-02-21 |
Hai Zong Yu
BRD | Director/Board Member | 60 | 19-03-23 |
Yun Pei Guo
BRD | Director/Board Member | 76 | 22-05-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-26 | 12.28 | +0.49% | 3 242 915 |
| 24-05-24 | 12.22 | -1.05% | 3,613,154 |
| 24-05-23 | 12.35 | -2.37% | 3,590,872 |
| 24-05-22 | 12.65 | +0.40% | 2,553,057 |
| 24-05-21 | 12.6 | -1.18% | 3,654,183 |
End-of-day quote Shanghai S.E., May 26, 2024
More quotes
HitGen Inc is a China-based company mainly engaged in the early research and development of original innovative drugs. The Company focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The Company mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The Company conducts its businesses within the domestic market and to overseas markets.
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.28
CNY
Average target price
16
CNY
Spread / Average Target
+30.29%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.08% | 674M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -0.29% | 21.78B | |
| -9.28% | 18.09B | |
| -41.70% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- 688222 Stock
